gms | German Medical Science

62nd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Polish Society of Neurosurgeons (PNCH)

German Society of Neurosurgery (DGNC)

7 - 11 May 2011, Hamburg

The role of the GNAS1 T393C polymorphism in patients with glioblastoma multiforme

Meeting Abstract

  • N. El Hindy - Abteilung für Neurochirurgie, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen
  • H.S. Bachmann - Institut für Pharmakogenetik, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen
  • N. Lambertz - Abteilung für Neurochirurgie, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen
  • Y. Zhou - Abteilung für Neurochirurgie, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen
  • U. Sure - Abteilung für Neurochirurgie, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen
  • I.E. Sandalcioglu - Abteilung für Neurochirurgie, Medizinische Fakultät, Universitätsklinikum Duisburg-Essen, Essen

Deutsche Gesellschaft für Neurochirurgie. Polnische Gesellschaft für Neurochirurgen. 62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH). Hamburg, 07.-11.05.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. DocP 091

DOI: 10.3205/11dgnc312, URN: urn:nbn:de:0183-11dgnc3122

Published: April 28, 2011

© 2011 El Hindy et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Genotypes of the T393C polymorphism of the GNAS1 locus encoding the G(alpha)s protein, which stimulates the formation of cyclic AMP (cAMP), were recently associated with the prognosis of different malignancies. We investigated a potential association of GNAS1 genotypes with survival of patients suffering from glioblastoma multiforme (GBM).

Methods: 162 patients suffering from GBM were retrospectively investigated. Inclusion criteria were availability of DNA and for patients still alive, a follow-up of at least 24 months. The results were evaluated with respect to the basic clinical data, type of surgical intervention (gross total resection versus biopsy), adjuvant therapy, MGMT-promoter methylation as well as survival at the 2-year follow-up.

Results: At the 2-year follow-up 127 (79.4%) of the 160 patients had died. CC homozygous patients had a 2-year survival rate of 15.8%, CT heterozygous patients of 23.1% and TT homozygous patients of 20.4% (p=0.461). Subgroup-analysis revealed different 2-year survival rates in the stereotactic subgroup with 0% for CC homozygous, 2.8% for CT heterozygous and 15.4% for TT homozygous patients, lacking statistical significance (p=0,229).

Conclusions: We could not reveal an association between the GNAS1 T393C polymorphism and the clinical course of patients suffering from glioblastoma.